C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

C4 Therapeutics (Nasdaq: CCCC) announced an inducement grant of non-qualified stock options to one new employee approved by the independent directors on the Organization, Leadership and Compensation Committee.

The grant covers 85,480 shares, was made on January 26, 2026, and has an exercise price equal to the closing price of C4T common stock on the grant date. The options vest over four years: 25% on the first-year anniversary of the employee's start date and the remainder in 36 equal monthly installments, subject to continued employment.

News Market Reaction

+3.38%

1 alert

+3.38% News Effect

On the day this news was published, CCCC gained 3.38%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement option grant: 85,480 shares Vesting schedule: 4 years Initial cliff vesting: 25% of shares +5 more

8 metrics

Inducement option grant 85,480 shares Non-qualified stock options granted to one new employee

Vesting schedule 4 years Inducement Grant vesting duration, subject to continued employment

Initial cliff vesting 25% of shares Vesting on first anniversary of employee start date

Subsequent vesting installments 36 monthly installments Remaining shares vest monthly after first-year anniversary

Exercise price basis Equal to closing price Exercise price set at C4T common stock closing price on Grant Date

Shelf registration capacity $400,000,000 Total amount under S-3 shelf filed Nov 21, 2025

ATM capacity within shelf $125,000,000 Common stock that may be issued via ATM program

Short interest days to cover 4.38 days Risk context metric provided for CCCC

Market Reality Check

Price: $1.90 Vol: Volume 769,195 is below t...

low vol

$1.90 Last Close

Volume Volume 769,195 is below the 20-day average of 1,561,880, suggesting limited trading interest ahead of this HR-related news. low

Technical Shares at $2.15 are trading slightly above the 200-day moving average of $2.10, while sitting 44.01% below the 52-week high and 98.16% above the 52-week low.

Peers on Argus

CCCC was down 1.38% while peers showed mixed moves: ELTX up 1.12%, NTHI up 3.11%...

CCCC was down 1.38% while peers showed mixed moves: ELTX up 1.12%, NTHI up 3.11%, TRDA down 1.55%, and SLS down 5.75%. With no peers in the momentum scanner and no same-day peer news, the move appears stock-specific rather than a coordinated sector reaction.

Historical Context

5 past events · Latest: Jan 14 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 14	Strategic roadmap	Positive	+0.9%	Outlined 2028 milestones for cemsidomide and discovery pipeline with cash runway.
Nov 25	Conference participation	Neutral	+0.8%	Announced fireside chat at Evercore healthcare conference with webcast access.
Nov 06	Earnings and update	Positive	+0.4%	Reported Q3 2025 results, $125M equity raise, and positive cemsidomide data.
Oct 16	Equity offering	Negative	+11.7%	Priced $125M underwritten offering with shares and multiple warrant classes.
Oct 01	Pfizer collaboration	Positive	-3.1%	Entered collaboration with Pfizer for Phase 1b cemsidomide–elranatamab trial.

Pattern Detected

Recent news has often been met with modest price changes, with positive clinical, financing, and strategic updates sometimes aligning with small gains but occasionally seeing negative or opposite reactions, indicating inconsistent news-to-price alignment.

Recent Company History

Over the last several months, C4 Therapeutics has reported financing, clinical, and strategic milestones. An October 2025 underwritten offering and related warrants provided substantial funding and was followed by a double‑digit percentage gain. Subsequent Q3 2025 results, collaboration updates with Pfizer, and a detailed 2028 milestone roadmap saw relatively modest price reactions, including both gains and declines. Today’s inducement option grant fits into routine corporate governance activity rather than a major clinical or financing catalyst.

Regulatory & Risk Context

Active S-3 Shelf · $400,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-21

$400,000,000 registered capacity

An effective S-3 shelf dated Nov 21, 2025 allows C4 Therapeutics to offer up to $400,000,000 of various securities, including up to $125,000,000 of common stock via an at-the-market program as part of that total, providing flexibility for future capital raises.

Market Pulse Summary

This announcement details a standard inducement equity award of 85,480 non-qualified stock options t...

Analysis

This announcement details a standard inducement equity award of 85,480 non-qualified stock options to a new employee under Nasdaq Listing Rule 5635(c)(4). The options vest over 4 years with a 25% first-year cliff and monthly vesting thereafter, using the Grant Date closing price as the exercise price. In context of prior financings and a $400,000,000 shelf, it represents routine compensation rather than a new capital-raising event.

Key Terms

non-qualified stock options, nasdaq listing rule 5635(c)(4), exercise price, vesting

4 terms

non-qualified stock options financial

"approved the grant of non-qualified stock options to purchase 85,480 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

nasdaq listing rule 5635(c)(4) regulatory

"Inducement Grant was granted as a material inducement ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"The Inducement Grant has an exercise price per share that is equal to the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The Inducement Grant will vest over a four-year period, with 25% of the shares vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. Not financial advice.

WATERTOWN, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the grant made on January 26, 2026 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Grant has an exercise price per share that is equal to the closing price of C4T’s common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the first-year anniversary of the employee’s start date, with the remainder of the shares vesting in thirty-six equal monthly installments thereafter, subject to the employee’s continued employment with C4T through each vesting date.

About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO^® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

Contacts:
Investors: 
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com

Media: 
Loraine Spreen 
Senior Director, Corporate Communications & Patient Advocacy 
LSpreen@c4therapeutics.com

FAQ

What did C4 Therapeutics (CCCC) announce on January 26, 2026?

C4 Therapeutics announced an inducement grant of non-qualified stock options for 85,480 shares to one new employee, granted on January 26, 2026 under Nasdaq Rule 5635(c)(4).

How is the C4 Therapeutics (CCCC) inducement grant priced?

The exercise price per share is set equal to the closing price of C4T common stock on January 26, 2026.

What is the vesting schedule for the C4 Therapeutics (CCCC) inducement options?

The options vest over four years: 25% vests on the first-year anniversary of employment and the remainder vests in 36 equal monthly installments thereafter, subject to continued employment.

Who approved the inducement grant at C4 Therapeutics (CCCC)?

The independent directors serving on the Organization, Leadership and Compensation Committee of the board approved the inducement grant.

Was the C4 Therapeutics (CCCC) grant made under Nasdaq rules and why?

Yes. The grant was made as a material inducement to hire the individual in accordance with Nasdaq Listing Rule 5635(c)(4).